Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 318-324

  Chen, Xuesong ^a   Meng, Qingwei ^a   Zhao, Yanbin ^a   Liu, Meiyan ^a   Li, Dandan ^a   Yang, Yanmei ^a   Sun, Lichun ^a   Sui, Guangjie ^a   Cai, Li ^a   Dong, Xiaoqun ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Angiotensin (AT) II; Angiotensin II type 1 receptor (AT1R); Breast cancer; Vascular endothelial growth factor (VEGF) A

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; VASCULOTROPIN A;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSARTAN; MCF-7 CELLS; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANGIOTENSIN, TYPE 1; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870317730     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.006     Document Type: Article

References (31)

1. Andersson T.M., Johansson A.L., Hsieh C.C., Cnattingius S., Lambe M. Increasing incidence of pregnancy-associated breast cancer in Sweden. Obstet. Gynecol. 2009, 114:568-572.
2. Arman M., Backman M. A longitudinal study on women's experiences of life with breast cancer in anthroposophical (complementary) and conventional care. Eur. J. Cancer Care (Engl.) 2007, 16:444-450.
3. Benns M.V., Luk T., Scoggins C.R. Surgical prophylaxis for inheritable malignant diseases: breast cancer and endocrine disease. Am. Surg. 2009, 75:529-536.
4. Guarneri V., Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009, 14:645-656.
5. Ogawa S., Kobori H., Ohashi N., Urushihara M., Nishiyama A., Mori T., Ishizuka T., Nako K., Ito S. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark. Insights 2009, 4:97-102.
6. Jing T., Wang H., Srivenugopal K.S., He G., Liu J., Miao L., He Y. Conditional expression of type 2 angiotensin II receptor in rat vascular smooth muscle cells reveals the interplay of the angiotensin system in matrix metalloproteinase 2 expression and vascular remodeling. Int. J. Mol. Med. 2009, 24:103-110.
7. Koh W.P., Yuan J.M., Sun C.L., van den Berg D., Seow A., Lee H.P., Yu M.C. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among chinese women in Singapore. Cancer Res. 2003, 63:573-578.
8. Lever A.F., Hole D.J., Gillis C.R., McCallum I.R., McInnes G.T., MacKinnon P.L., Meredith P.A., Murray L.S., Reid J.L., Robertson J.W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet 1998, 352:179-184.
9. Wang L., Cai S.R., Zhang C.H., He Y.L., Zhan W.H., Wu H., Peng J.J. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin. Med. J. (Engl.) 2008, 121:2167-2171.
10. Takeda H., Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am. J. Pathol. 2001, 158:1633-1637.
11. Kikkawa F., Mizuno M., Shibata K., Kajiyama H., Morita T., Ino K., Nomura S., Mizutani S. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am. J. Obstet. Gynecol. 2004, 190:1258-1263.
12. Suganuma T., Ino K., Shibata K., Kajiyama H., Nagasaka T., Mizutani S., Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005, 11:2686-2694.
13. Dinh D.T., Frauman A.G., Sourial M., Casley D.J., Johnston C.I., Fabiani M.E. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001, 142:1349-1356.
14. Rhodes D.R., Ateeq B., Cao Q., Tomlins S.A., Mehra R., Laxman B., Kalyana-Sundaram S., Lonigro R.J., Helgeson B.E., Bhojani M.S., Rehemtulla A., Kleer C.G., Hayes D.F., Lucas P.C., Varambally S., Chinnaiyan A.M. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA 2009, 106:10284-10289.
15. Shimizu T., Videman T., Shimazaki K., Mooney V. Experimental study on the repair of full thickness articular cartilage defects: effects of varying periods of continuous passive motion, cage activity, and immobilization. J. Orthop. Res. 1987, 5:187-197.
16. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 1995, 36:169-180.
17. Batra V.K., Gopalakrishnan V., McNeill J.R., Hickie R.A. Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. Cancer Lett. 1994, 76:19-24.
18. Imai N., Hashimoto T., Kihara M., Yoshida S., Kawana I., Yazawa T., Kitamura H., Umemura S. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab. Invest. 2007, 87:189-198.
19. Sidorkiewicz M., Rebas E., Szymajda M., Lawnicka H., Pawlikowski M., Lachowicz A. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor. Med. Sci. Monit. 2009, 15:BR106-BR110.
20. De Paepe B., Verstraeten V.L., De Potter C.R., Vakaet L.A., Bullock G.R. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell Biol. 2001, 116:247-254.
21. Linderholm B.K., Lindahl T., Holmberg L., Klaar S., Lennerstrand J., Henriksson R., Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 2001, 61:2256-2260.
22. Nouet S., Amzallag N., Li J.M., Louis S., Seitz I., Cui T.X., Alleaume A.M., Di Benedetto M., Boden C., Masson M., Strosberg A.D., Horiuchi M., Couraud P.O., Nahmias C. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J. Biol. Chem. 2004, 279:28989-28997.
23. Uemura H., Ishiguro H., Nakaigawa N., Nagashima Y., Miyoshi Y., Fujinami K., Sakaguchi A., Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003, 2:1139-1147.
24. Wruck C.J., Funke-Kaiser H., Pufe T., Kusserow H., Menk M., Schefe J.H., Kruse M.L., Stoll M., Unger T. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler. Thromb. Vasc. Biol. 2005, 25:57-64.
25. Du N., Feng J., Hu L.J., Sun X., Sun H.B., Zhao Y., Yang Y.P., Ren H. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol. Rep. 2012, 27:1893-1903.
26. Tanaka N., Miyajima A., Kosaka T., Shirotake S., Hasegawa M., Kikuchi E., Oya M. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol. Cancer Ther. 2010, 9:2982-2992.
27. Neo J.H., Malcontenti-Wilson C., Muralidharan V., Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J. Gastroenterol. Hepatol. 2007, 22:577-584.
28. Kosugi M., Miyajima A., Kikuchi E., Horiguchi Y., Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin. Cancer Res. 2006, 12:2888-2893.
29. Miyajima A., Kosaka T., Asano T., Seta K., Kawai T., Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002, 62:4176-4179.
30. Lorusso V. Bevacizumab in the treatment of HER2-negative breast cancer. Biologics 2008, 2:813-821.
31. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17:265-272.